Business Wire

CA-HYPERICE

8.11.2021 12:02:07 CET | Business Wire | Press release

Share
Rory McIlroy, Daniel Ricciardo, Connor McDavid, Klay Thompson, Jayson Tatum and More Join Naomi Osaka, Erling Haaland and Virat Kohli as Hyperice Athlete-Investors to Fuel Global Growth

Hyperice , a global high-performance wellness brand specializing in percussion, dynamic air compression, vibration, thermal technology, mind technology, and contrast therapy, today announced new investments from superstars across the sports world including professional golfer Rory McIlroy , Formula One (F1) driver Daniel Ricciardo , NHL player Connor McDavid , NBA player Klay Thompson and NBA player Jayson Tatum .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211108005407/en/

The new investors join an elite list of global athlete-investors such as 4-time tennis Grand Slam champion Naomi Osaka, football superstar Erling Haaland and Indian cricketer Virat Kohli as strategic investors, and quickly follows the company’s entry to mental wellness and evolution into a holistic high-performance wellness brand .

“I am a golfer first and foremost but I am also focused on the long game, which is why I chose to invest in Hyperice,” said professional golfer Rory McIlroy. “Hyperice is an important part of how I practice, play and recover. The company is doing incredible things to redefine and push holistic wellness, so it is an exciting and logical partnership for me and investment partners in Symphony Ventures.”

Other new athlete-investors include 2x NBA All-Star Jayson Tatum, 2x PGA TOUR Champion Tony Finau, 3x NBA Champion Klay Thompson, NBA Champion Khris Middleton, 6x MLB All-Star Nolan Arenado, MLB All-Star Matt Chapman, 4x MLB All-Star Justin Upton, World Series Champion Dexter Fowler, The Masters Champion Sergio Garcia, Professional BMX Athlete Nigel Sylvester, Master Trainer and Performance Specialist Joe Holder, top gaming personality Nicholas Kolcheff, known as NICKMERCS, and more.

These athletes join Hyperice’s current roster of existing high-performing athlete-investors such as Naomi Osaka, Seth Curry, Anthony Davis, Rickie Fowler, DeAndre Jordan, Jarvis Landry, Patrick Mahomes, Christian McCaffrey, Ja Morant, Chris Paul, Ben Simmons, Kelly Slater, Fernando Tatís Jr, J.J. Watt, Russell Westbrook and Trae Young.

“Hyperice’s full suite of products have made a big difference in my recovery and my entire approach to wellness,” said Formula One (F1) driver Daniel Ricciardo. “As Hyperice continues to expand, it felt like the right time to officially put my support into a company that I believe in.”

Now with a global footprint in more than 60 countries, Hyperice is experiencing dramatic global growth driven by an extensive athlete-investors roster, as well as global partnerships in China with the NBA and Leagues of Legends Pro League, the New Zealand national rugby team All Blacks, South Africa national rugby team Springboks, the Mexican Football Federation, and the Tottenham Hotspur Football Club in London.

Reigning National Hockey League (NHL) Most Valuable Player Connor McDavid added: “Hyperice products are a game changer when it comes to supporting both my physical and mental health. Hyperice is not only a brand I personally rely on, but it offers products that benefit all people, no matter what level of athlete they are.”

“This new group of strategic investors will help to fuel Hyperice’s global expansion,” said Jim Huether, Hyperice CEO. “Our international footprint continues to grow with products in more than 60 countries. Partnering with high-performing global athletes like Daniel Ricciardo, Rory McIlroy, Connor McDavid, in addition to the stacked roster we already have, helps continue to separate Hyperice as we continue bringing our innovative suite of products to a broader audience.”

Global Growth and Holistic High-Performance Wellness Brand Evolution

Hyperice recently announced a new stage of global growth as the company evolves into a holistic high-performance wellness brand. The multi-prong transformation, led by Hyperice’s recent acquisition of mental wellness company Core , its third acquisition in the last 18 months, is accompanied by a new brand identity and global brand campaign, and anchored by a suite of new products and industry-first technologies.

Among the new technology advancements include the world's first portable contrast therapy device, Hyperice X, and new generations of Hyperice’s wildly popular Hypervolt and Vyper lines, including the Hypervolt 2, Hypervolt 2 Pro, Vyper 3 and Vyper Go.

  • Hyperice X : Last month, Hyperice introduced its latest innovation and the world's first portable contrast therapy device. Hyperice X creates a localized cycle of alternating heat and cold to the knee area for recovery and rehabilitation. Hyperice X will be available globally beginning in 2022.
  • Hypervolt 2: The Hypervolt 2 offers noticeable updates from the original, including an improved ergonomic design and reduced weight. Three speeds of powerful percussion help give muscles the relief they’ve been asking for, every day.
  • Hypervolt 2 Pro : With the Hypervolt 2 Pro, users will get the same powerful percussion massage therapy that the world’s best athletes have, right in the palm of their hand. Five speeds, set by a new adjustable dial, provide relief to stiff muscles, so users can train and recover like a pro.
  • Vyper 3 : All systems activated. The Vyper 3 vibrating roller’s updated design and three speeds help to prime and warm-up the body with a powerful vibrating massage.
  • Vyper Go : The next iteration of Hyperice’s “Go” line. Following the release of the Hypervolt Go in 2020, the Vyper Go is a portable, vibrating roller that helps activate muscles, so users can feel their best before activity at home or on the go.

The Vyper 3 is now available in Europe and the United States, and the Hypervolt 2, Hypervolt 2 Pro and Vyper Go are now available in Australia, Canada, China, Europe, New Zealand and the United States with other markets to follow.

Hyperice’s new modern approach and reimagined product innovation allows Hyperice to reimagine how it serves a broader audience of athletes and helps people everywhere do the things they love, and do it more.

For more information, visit hyperice.com. To purchase, please visit country-specific sites: Australia , Canada , China , France , Germany , Italy , New Zealand , Portugal , Spain , UK and the United States .

About Hyperice

Hyperice is a technology-driven company with a giant mission, to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specializing in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), mind technology (Core by Hyperice) and contrast therapy (Hyperice X). Now, as a holistic high-performance wellness brand, Hyperice is designed for all - from the most elite athletes, leagues and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognized as one of Fast Company’s Most Innovative Companies in 2021, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physical therapy, sports performance and workplace wellness on a global scale. Hyperice’s transformative acquisitions of Normatec, RecoverX and Core have helped to accelerate its innovation agenda as it enters its next stage of global growth. For more information, visit the newly redesigned hyperice.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

Seoul Viosys Eyes the $60 Billion AI Data Center Optical Communication Market with Opto Semiconductors27.4.2026 15:00:00 CEST | Press release

Joint Development Talks with Global Optical Communications companiesExpanding Partnerships to Provide Total Transceiver Solution1,800 Patents Secured for High-Performance Optical Communications Seoul Viosys (KOSDAQ: 092190), a company specializing in opto-semiconductor devices, is accelerating its entry into the next-generation photonics market supported by its proprietary “No-wire” and “No-package” fundamental patents—essential technologies for micrometer (μm)-scale miniaturization of opto-semiconductors—as well as its competitiveness in VCSEL technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426926495/en/ Seoul Viosys Optoelectronic Semiconductor Structure Subject to a Permanent U.S. Injunction in February 2026, Covering Similar Products and Employees (Image: Seoul Viosys) As the rapid expansion of AI drives a paradigm shift in data centers from copper-based to optical-based architectures, the company is streng

vVARDIS Announces Investment from Apollo—Achieves Unicorn Status27.4.2026 14:51:00 CEST | Press release

Investment will support global commercial expansion of the Curodont™ technology platform, the first and only non-invasive peptide-containing formulations designed to treat tooth decay drill-free throughout the depth of the lesion vVARDIS Holding AG (“vVARDIS”), a high-growth dental medtech company pioneering non-invasive cavity treatment, today announced a strategic minority investment from Apollo-managed funds (“Apollo Funds”). The investment will support vVARDIS’ next phase of global growth and commercial expansion, including the continued rollout of its Curodont™ suite of products. The investment establishes vVARDIS as one of Europe’s few privately owned, billion-dollar-plus, healthcare companies. vVARDIS’ founders and co-CEOs, Drs. Haley and Goly Abivardi, will retain a substantial majority shareholding in the company. vVARDIS is redefining the treatment of cavities through its Curodont™ technology, the first and only commercially available non-invasive peptide-containing formulati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye